COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Fundamental Risk Analysis including financial ratios, debt levels, liquidity, and sustainability metrics. Compare against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Fundamental Risk Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.

Debt-to-Equity Ratio

0.04

Decreased from previous period

D/E ratio exceeding 1.5x Medical - Pharmaceuticals median of 0.02. Howard Marks would check for debt covenant compliance and refinancing risks.

Net Debt-to-EBITDA

-2.05

Increased from previous period

Net cash position versus Medical - Pharmaceuticals median net debt of 1.60. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.

Interest Coverage Ratio

257.54

Increased from previous period

Coverage of 257.54 versus zero Medical - Pharmaceuticals median interest expense. Walter Schloss would verify if our leverage provides advantages.

Current Ratio

0.72

Decreased from previous period

Current ratio below 50% of Medical - Pharmaceuticals median of 1.54. Michael Burry would check for immediate refinancing needs.

Intangibles-to-Total-Assets Ratio

0.78%

Increased from previous period

Intangibles 50-90% of Medical - Pharmaceuticals median of 1.33%. Charlie Munger would examine if industry dynamics justify more tangible-heavy model.

Select Chart Metric:

3349.T Fundamental Risk Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Debt-to-Equity Ratio

0.04

Decreased from previous period

D/E ratio exceeding 1.5x Medical - Pharmaceuticals median of 0.02. Howard Marks would check for debt covenant compliance and refinancing risks.

Net Debt-to-EBITDA

-2.05

Increased from previous period

Net cash position versus Medical - Pharmaceuticals median net debt of 1.60. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.

Interest Coverage Ratio

257.54

Increased from previous period

Coverage of 257.54 versus zero Medical - Pharmaceuticals median interest expense. Walter Schloss would verify if our leverage provides advantages.

Current Ratio

0.72

Decreased from previous period

Current ratio below 50% of Medical - Pharmaceuticals median of 1.54. Michael Burry would check for immediate refinancing needs.

Intangibles-to-Total-Assets Ratio

0.78%

Increased from previous period

Intangibles 50-90% of Medical - Pharmaceuticals median of 1.33%. Charlie Munger would examine if industry dynamics justify more tangible-heavy model.

Select Chart Metric: